1. Denmark Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
H. Lundbeck A/S

H. Lundbeck A/S

HLBBF
H. Lundbeck A/SUS flagOther OTC
6.60
USD
- -
- -
5.23BMarket Cap
H. Lundbeck A/S
HLBBF
(Other OTC)

Recent

price

6.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
75.29
81.63
75.47
77.79
68.63
74.28
79.29
87.52
89.97
87.36
88.92
16.41
18.38
20.07
22.19
24.83
25.69
Revenue per Share
12.57
11.64
5.94
4.36
-0.78
-28.98
6.14
13.29
19.67
11.64
7.96
1.33
1.93
2.31
3.17
3.22
3.72
Basic EPS, GAAP
12.43
10.26
2.36
11.45
0.31
-14.04
14.12
16.81
26.56
10.9
16.9
1.67
2.72
3.61
2.78
4.9
5.48
Free Cash Flow per Basic Share
3.07
3.77
3.49
2
2.77
- -
- -
2.45
8
12
4.1
0.5
0.4
0.58
0.7
0.95
1.15
Dividend per Share
57.02
64.94
67.2
69.72
65.63
37.07
44.42
56.53
67.97
80.4
84.26
17.69
19.32
21.04
23.53
25.81
26.25
Book Value per Share
15.86
22.09
21.26
22.45
4.36
-5.14
4.34
23.37
31.35
-47.68
-29.01
-4.5
-1.73
1.36
-16.16
-10.96
-10.57
Tangible Book Value per Share
196
196
196
196
196
196
197
198
199
199
199
993
993
992
991
992
993
Basic Weighted Avg Shares
14,765
16,007
14,802
15,258
13,468
14,594
15,634
17,286
17,875
17,358
17,672
16,299
18,246
19,912
22,004
24,630
25,520
Sales/Revenue/Turnover
22.74
21.2
11.66
10.48
0.74
-46.7
14.66
25.8
28.3
20.02
11.26
12.33
15.63
16.05
14.86
21.42
22.46
Operating Margin (%)
1,036
1,235
888
- -
1,453
7,026
1,554
- -
- -
1,670
2,793
1,710
1,811
2,012
1,876
1,865
- -
Depreciation Expense
2,466
2,282
1,165
855
-153
-5,694
1,211
2,624
3,907
2,313
1,581
1,318
1,916
2,290
3,143
3,192
3,698
Net Income, GAAP
25.02
30.79
29.86
41.92
- -
- -
43.86
38.65
26.13
23.56
17.05
16.64
22.55
23.49
15.49
28.86
28
Effective Tax Rate (%)
16.7
14.26
7.87
5.6
-1.14
-39.02
7.75
15.18
21.86
13.33
8.95
8.09
10.5
11.5
14.28
12.96
14.49
Profit Margin (%)
2,709
4,107
4,200
4,845
2,184
-88
-252
2,365
4,073
-1,242
93
-206
3,213
5,299
4,430
3,930
3,656
Working Capital
1,918
1,907
1,890
2,141
3,259
3,687
1,708
57
- -
7,499
5,813
5,236
5,491
4,065
16,611
11,580
10,854
LT Debt
11,122
12,776
13,198
13,481
13,526
8,785
9,694
12,181
14,251
16,782
16,973
18,279
20,779
22,045
25,010
24,903
25,626
Total Equity
19.72
16.84
8.1
6.04
- -
- -
10.6
22.82
28.14
12.9
6.3
6.76
8.67
9.12
8.04
9.48
10.75
Return on Invested Capital (%)
20.21
16.87
8.86
6.59
- -
- -
12.74
25.75
31.6
12.09
6.9
6.08
8.38
9.36
9.96
9.21
9.77
Return on Capital (%)
24.04
19.08
8.99
6.37
-1.15
-56.48
15.1
26.34
31.68
15.69
9.66
7.68
10.43
11.43
14.22
13.04
14.91
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
76
74
74
LT Borrowings
11,924
11,185
10,446
LT Finance Leases
408
395
408
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
992
992
992
Market Capitalization
45,671
43,426
39,813

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
13,359
12,783
12,647
Cash, Cash Equivalents & STI
3,479
3,433
1,956
Accounts Receivable, Net
5,609
3,605
6,092
Inventories
4,271
4,473
4,599
Total Current Liabilities
9,104
8,853
8,991
Payables & Accruals
- -
- -
- -
ST Debt
76
74
74
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.24%
8.1%
-0.43%
Free Cash Flow
-2.87%
19.58%
76.13%
Net Income, GAAP
5.89%
17.41%
1.56%
Sales/Revenue/Turnover
5.58%
7.15%
11.93%
Total Cash Common Dividend
- -
8.46%
35.88%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,288
5,453
5,722
5,541
22,004
2025
6,235
6,023
6,279
6,093
24,630
2026
7,125
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.01
0.78
0.78
- -
3.17
2025
1.13
0.97
1.11
- -
3.22
2026
1.67
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.7
- -
- -
- -
0.7
2025
0.95
- -
- -
- -
0.95
2026
1.15
- -
- -
- -
- -
Similar Companies
Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
Indoco Remedies Limited (INDOCO.NS)
WDB coco Co., Ltd. (7079.T)
Apeloa Pharmaceutical Co.,Ltd (000739.SZ)
Vibe Growth Corporation (VIBE.CN)
Kamada Ltd. (KMDA.TA)
Business
H. Lundbeck A/S, a Denmark-based international pharmaceutical company founded in 1915 and headquartered in Valby, Copenhagen, specializes in the research, development, manufacturing, marketing, and sale of innovative therapeutics for brain diseases including psychiatric and neurological disorders. The company operates in more than 50 countries with production facilities in Denmark, France, and Italy, research centers in Denmark and the USA, and products registered in over 100 countries worldwide. Its core portfolio encompasses treatments across multiple disease areas: for Parkinson's disease, Azilect (rasagiline); for alcohol dependence, Selincro (nalmefene); for Alzheimer's disease, Ebixa/Ebix/Abixa/Memantine Merz (memantine); for migraine, Vyepti (eptinezumab); for epilepsy, Sabril (vigabatrin), Onfi/Frisium (clobazam); for depression and anxiety, Rexulti/Rxulti (brexpiprazole), Brintellix/Trintellix/Fonksera/Vortioson/Vurtuoso (vortioxetine), Cipralex/Lexapro/Sipralexa/Seroplex/Entact/Lepax/Premalex/Prilect/Esipram/Esertia/Rhea Escitalopram (escitalopram oxalate), Cipramil/Seropram/Cipram/Sepram/Celexa/Elopram/Prisdal (citalopram), Deanxit (flupentixol + melitracene), Noritren/Nortrilen/Sensaval (nortriptyline), and Saroten/Sarotex/Redomex/Sarotena (amitriptyline); for psychosis, Rexulti/Rxulti (brexpiprazole), Abilify Maintena (aripiprazole), Serdolect (sertindole), Cisordinol/Clopixol/Ciatyl-Z (zuclopenthixol), Cisordinol Depot/Clopixol Depot/Ciatyl-Z Depot (zuclopenthixol decanoate), Fluanxol Depot/Depixol/Fluanxol LP/Fluanxol Retard (cis(Z)-flupentixol decanoate), Fluanxol/Fluanxol Mite/Depixol (flupentixol), Truxal (chlorprothixene), and Cisordinol-Acutard/Clopixol-Acutard/Clopixol-Acuphase/Ciatyl-Z-Acuphase (zuclopenthixol acetate); and for other indications, Northera (droxidopa). In recent developments, Lundbeck completed the acquisition of Longboard Pharmaceuticals in 2024 for approximately $2.6 billion, significantly enhancing its neuroscience pipeline; announced a restructuring of commercial operations impacting over 600 international employees to adopt a partner-model for global markets; and raised its full-year 2025 financial guidance for revenue and adjusted EBITDA growth at constant exchange rates, supported by strong year-to-date revenue increases driven by key brands like Vyepti. The Lundbeck Foundation maintains majority ownership of approximately 69%.

Company News

APIChatGPT

  • seekingalpha.com

    H. Lundbeck A/S (HLBBF) Discusses PROCEED Trial Results and Data Presented at AHS on Bokunebart for Headache Treatment Transcript

  • seekingalpha.com

    H. Lundbeck A/S (HLBBF) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    H. Lundbeck A/S (HLBBF) Q4 2025 Earnings Call Transcript

  • wsj.com

    H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal

  • seekingalpha.com

    H. Lundbeck A/S (HLBBF) Q3 2025 Earnings Call Transcript

  • prnewswire.com

    Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan